pac.dog pac.dog / Bills

HR 1672 — Maintaining Investments in New Innovation Act

Congress 119

Latest action: — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Sponsors

Lobbied by (11)

LDA filings that named this bill in their activity descriptions. The lobbying firm (registrant) is paid by the client to lobby on this and related issues.

FilingPeriodRegistrant (lobbying firm)ClientIncomeMatched
1st Quarter - Report2026 first_quarterFORBES-TATENOVARTIS, INC.$50,000H.R. 1672
1st Quarter - Report2026 first_quarterTIBER CREEK GROUPALNYLAM PHARMACEUTICALS, INC.$60,000H.R. 1672
1st Quarter - Report2026 first_quarterLMH STRATEGIC SOLUTIONSIONIS PHARMACEUTICALS, INC.$30,000H.R.1672
1st Quarter - Report2026 first_quarterLMH STRATEGIC SOLUTIONSALNYLAM PHARMACEUTICALS, INC.$50,000H.R.1672
1st Quarter - Amendment2026 first_quarterVENABLE LLPASSOCIATION OF BLACK CARDIOLOGISTS$30,000H.R. 1672
1st Quarter - Report2026 first_quarterHARMONY BIOSCIENCESHARMONY BIOSCIENCES—HR 1672
1st Quarter - Report2026 first_quarterTHE ALS ASSOCIATIONTHE ALS ASSOCIATION—H.R.1672
1st Quarter - Report2026 first_quarterHEALTHCARE INSTITUTE OF NEW JERSEYHEALTHCARE INSTITUTE OF NEW JERSEY—H.R. 1672
1st Quarter - Report2026 first_quarterVENABLE LLPASSOCIATION OF BLACK CARDIOLOGISTS$30,000H.R. 1672
1st Quarter - Report2026 first_quarterIONIS PHARMACEUTICALS, INC.IONIS PHARMACEUTICALS, INC.—H.R.1672
1st Quarter - Report2026 first_quarterPUBLIC CITIZENPUBLIC CITIZEN—H.R.1672

Action timeline

  1. · H11100 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  2. · H11100 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  3. · Intro-H — Introduced in House
  4. · 1000 — Introduced in House

Text versions

Connected on the graph

Inbound (19)

datefromtypeamountrolesource
—Hinson, Ashleycosponsor_of_bill—cosponsorsponsorship
—Fong, Vincecosponsor_of_bill—cosponsorsponsorship
—Fleischmann, Charles J. "Chuck"cosponsor_of_bill—cosponsorsponsorship
—Moolenaar, John R.cosponsor_of_bill—cosponsorsponsorship
—Lawler, Michaelcosponsor_of_bill—cosponsorsponsorship
—Hern, Kevincosponsor_of_bill—cosponsorsponsorship
—Yakym, Rudycosponsor_of_bill—cosponsorsponsorship
2026-01-01ASSOCIATION OF BLACK CARDIOLOGISTSlobbies_on_bill—H.R. 1672lobbying_bill_mention
2026-01-01ASSOCIATION OF BLACK CARDIOLOGISTSlobbies_on_bill—H.R. 1672lobbying_bill_mention
2026-01-01IONIS PHARMACEUTICALS, INC.lobbies_on_bill—H.R.1672lobbying_bill_mention
2026-01-01ALNYLAM PHARMACEUTICALS, INC.lobbies_on_bill—H.R.1672lobbying_bill_mention
2026-01-01HARMONY BIOSCIENCESlobbies_on_bill—HR 1672lobbying_bill_mention
2026-01-01THE ALS ASSOCIATIONlobbies_on_bill—H.R.1672lobbying_bill_mention
2026-01-01ALNYLAM PHARMACEUTICALS, INC.lobbies_on_bill—H.R. 1672lobbying_bill_mention
2026-01-01IONIS PHARMACEUTICALS, INC.lobbies_on_bill—H.R.1672lobbying_bill_mention
2026-01-01HEALTHCARE INSTITUTE OF NEW JERSEYlobbies_on_bill—H.R. 1672lobbying_bill_mention
2026-01-01PUBLIC CITIZENlobbies_on_bill—H.R.1672lobbying_bill_mention
2026-01-01NOVARTIS, INC.lobbies_on_bill—H.R. 1672lobbying_bill_mention
2025-02-27Davis, Donald G.sponsor_of_bill—sponsorsponsorship

Who matters

Members ranked by combined influence on this bill: role (sponsor 5 / cosponsor 1), capped speech count from the Congressional Record, and recorded-vote engagement.

#MemberRoleSpeechesVotedScore
1Davis, Donald G. (D, house NC-1)sponsor3—8
2Lawler, Michael (R, house NY-17)cosponsor1—2
3Fleischmann, Charles J. "Chuck" (R, house TN-3)cosponsor0—1
4Fong, Vince (R, house CA-20)cosponsor0—1
5Hern, Kevin (R, house OK-1)cosponsor0—1
6Hinson, Ashley (R, house IA-2)cosponsor0—1
7Moolenaar, John R. (R, house MI-2)cosponsor0—1
8Yakym, Rudy (R, house IN-2)cosponsor0—1

Who's influencing them

Orgs ranked by combined money flow on this bill: LDA filings citing the bill + individual contributions in cycle 2026from donors whose employer matches the org name (Schedule A) to any principal committee in the "who matters" list above.

#OrgLDA filingsLDA spendDonor employeesEmployee donationsTotal
1ALNYLAM PHARMACEUTICALS, INC.2$110,0000$0$110,000
2ASSOCIATION OF BLACK CARDIOLOGISTS2$60,0000$0$60,000
3NOVARTIS, INC.1$50,0000$0$50,000
4retired0$0415$31,582$31,582
5IONIS PHARMACEUTICALS, INC.2$30,0000$0$30,000
6castle harlan, inc.0$01$7,000$7,000
7not employed0$011$3,926$3,926
8s-3 group0$01$3,700$3,700
9berenson partners, llc.0$01$3,643$3,643
10method security0$01$3,500$3,500
11dragonfly0$01$3,500$3,500
12ohio machinery co.0$01$3,500$3,500
13thirdpoint llc0$01$3,500$3,500
14heritage construction + materials0$01$3,300$3,300
15northwell health0$02$3,000$3,000
16thorsen french advocacy0$02$3,000$3,000
17self employed0$08$2,971$2,971
18united states hispanic business counci0$01$2,500$2,500
19none0$011$2,410$2,410
20aurora0$02$2,000$2,000
21healthcare0$01$2,000$2,000
22cordary inc.0$01$2,000$2,000
23brownstein, hyatt, forder, schreck0$01$1,500$1,500
24regency centers0$01$1,500$1,500
25canada life reinsurance company0$01$1,250$1,250

Predicted vote

Aggregated from: actual roll-call votes (when present) → sponsor → cosponsor → party median (predicts YES when ≥25% of the caucus sponsored/cosponsored). Each row labels its confidence tier so you can see why a position was predicted.

8 predicted yes (1%) · 3 predicted no (1%) · 532 unknown (98%)

By party: · R: 7 yes / 0 no / 270 unknown · D: 1 yes / 0 no / 262 unknown · I: 0 yes / 3 no

8 high-confidence positions (voted + sponsor + cosponsor)

Activity

Every typed-graph event involving this entity, newest first. Each row is one edge in the influence graph; click the date to jump to its provenance.

  1. 2026-05-17 · cosponsored by Hern, Kevin (cosponsor) · sponsorship
  2. 2026-05-17 · cosponsored by Fleischmann, Charles J. "Chuck" (cosponsor) · sponsorship
  3. 2026-05-17 · cosponsored by Yakym, Rudy (cosponsor) · sponsorship
  4. 2026-05-17 · cosponsored by Moolenaar, John R. (cosponsor) · sponsorship
  5. 2026-05-17 · cosponsored by Lawler, Michael (cosponsor) · sponsorship
  6. 2026-05-17 · cosponsored by Hinson, Ashley (cosponsor) · sponsorship
  7. 2026-05-17 · cosponsored by Fong, Vince (cosponsor) · sponsorship
  8. 2026-01-01 · lobbied on by ALNYLAM PHARMACEUTICALS, INC. (h.r. 1672) · lobbying_bill_mention
  9. 2026-01-01 · lobbied on by NOVARTIS, INC. (h.r. 1672) · lobbying_bill_mention
  10. 2026-01-01 · lobbied on by THE ALS ASSOCIATION (h.r.1672) · lobbying_bill_mention
  11. 2026-01-01 · lobbied on by ASSOCIATION OF BLACK CARDIOLOGISTS (h.r. 1672) · lobbying_bill_mention
  12. 2026-01-01 · lobbied on by IONIS PHARMACEUTICALS, INC. (h.r.1672) · lobbying_bill_mention
  13. 2026-01-01 · lobbied on by ASSOCIATION OF BLACK CARDIOLOGISTS (h.r. 1672) · lobbying_bill_mention
  14. 2026-01-01 · lobbied on by IONIS PHARMACEUTICALS, INC. (h.r.1672) · lobbying_bill_mention
  15. 2026-01-01 · lobbied on by ALNYLAM PHARMACEUTICALS, INC. (h.r.1672) · lobbying_bill_mention
  16. 2026-01-01 · lobbied on by PUBLIC CITIZEN (h.r.1672) · lobbying_bill_mention
  17. 2026-01-01 · lobbied on by HARMONY BIOSCIENCES (hr 1672) · lobbying_bill_mention
  18. 2026-01-01 · lobbied on by HEALTHCARE INSTITUTE OF NEW JERSEY (h.r. 1672) · lobbying_bill_mention
  19. 2025-02-27 · sponsored by Davis, Donald G. (sponsor) · sponsorship

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.

Estimated value: $180/mo per user — but we made it free.